-
A proposal for a simplified measure of HIV preexposure prophylaxis prevention-effective adherence in self-report questionnaires. AIDS (IF 3.8) Pub Date : 2024-03-14 Doug Fraser, Martin Holt, Jason J Ong, Christopher Bourne, Curtis Chan, Andrew E Grulich, Benjamin R Bavinton
Evaluating HIV preexposure prophylaxis (PrEP) use and HIV risk events concurrently remains challenging. We developed a single question method for measuring prevention-effective adherence with PrEP in self-report questionnaires. In a questionnaire completed by 409 gay and bisexual men, 46% reported condomless anal sex that was not covered by their own PrEP use, and this was more common among younger
-
Adverse drug reaction profile of third-generation smallpox vaccines used in France during the 2022 monkeypox epidemic. AIDS (IF 3.8) Pub Date : 2024-03-14 Audrey Fresse, Nathalie Massy, Dorine Fournier, Sylvine Pinel, Mathilde Beurrier, Marie-Lauren Antoine, Nadine Petitpain, Pierre Gillet
Due to the start of the monkeypox epidemic in 2022, we retrospectively analyzed the adverse drug reactions (ADRs) reported in France after monkeypox vaccinations with the third-generation smallpox vaccine. Ninety-eight cases, representing 172 ADRs, were reported. ADRs were mostly expected reactogenicity reactions occurring within days after the first dose of vaccine and having a quick favorable outcome
-
Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trial. AIDS (IF 3.8) Pub Date : 2024-03-04 Sufia Dadabhai, Victoria B Chou, Mauricio Pinilla, Lameck Chinula, Maxensia Owor, Avy Violari, Dhayendre Moodley, Lynda Stranix-Chibanda, Taguma Allen Matubu, Gift Tafadzwa Chareka, Gerhard Theron, Aarti Avinash Kinikar, Mwangelwa Mubiana-Mbewe, Lee Fairlie, Raziya Bobat, Blandina Theophil Mmbaga, Patricia M Flynn, Taha E Taha, Katie S McCarthy, Renee Browning, Lynne M Mofenson, Sean S Brummel, Mary
IMPAACT 1077BF/FF compared the safety/efficacy of two HIV antiretroviral therapy (ART) regimens to zidovudine (ZDV) alone during pregnancy for HIV prevention. PROMISE found an increased risk of preterm delivery (<37 weeks) with antepartum triple ART (TDF/FTC/LPV+r or ZDV/3TC/LPV+r) compared to ZDV alone. We assessed the impact of preterm birth, breastfeeding and antepartum ART regimen on 24-month infant
-
Trends in HIV preexposure prophylaxis utilization and spending among individuals with commercial insurance. AIDS (IF 3.8) Pub Date : 2024-02-29 Sean Dickson, Katelyn James
In a cross-sectional analysis of HIV preexposure prophylaxis (PrEP) utilization by commercially insured patients from 2019 to 2021, most prescriptions were for branded formulations of PrEP despite the availability of a generic version. Accounting for the modest relative clinical benefit of branded TAF/FTC (tenofovir alafenamide fumarate/emtricitabine) PrEP over generic TDF/FTC (tenofovir disoproxil
-
Systemic inflammation in pregnant women with HIV: relationship with HIV treatment regimen and preterm delivery. AIDS (IF 3.8) Pub Date : 2024-02-26 Rupak Shivakoti, Mark J Giganti, Michael M Lederman, Rachel Ketchum, Sean Brummel, Daniela Moisi, Sufia Dadabhai, Dhayendre Moodley, Avy Violari, Lameck Chinula, Maxensia Owor, Amita Gupta, Judith S Currier, Taha E Taha, Mary Glenn Fowler
: HIV treatment regimen during pregnancy was associated with preterm delivery (PTD) in the PROMISE 1077 BF trial. Systemic inflammation among pregnant women with HIV could help explain differences in PTD by treatment regimen. We assessed associations between inflammation, treatment regimen, and PTD.
-
Brain N-acetyl-aspartyl-glutamate (NAAG) is associated with cognitive function in older virally-suppressed people with HIV. AIDS (IF 3.8) Pub Date : 2024-02-22 Robyn L Wiseman, Kristin L Bigos, Raha M Dastgheyb, Peter B Barker, Leah H Rubin, Barbara S Slusher
: Cognitive impairment persists in virally-suppressed people with HIV (VS-PWH) especially in higher order domains. One cortical circuit, linked to these domains, is regulated by N-acetyl-aspartyl glutamate (NAAG), the endogenous agonist of the metabotropic glutamate receptor 3. The enzyme glutamate carboxypeptidase II (GCPII) catabolizes NAAG and is upregulated in aging and disease. Inhibition of GCPII
-
The relationship of age and comorbid conditions to hospital and nursing home days in Medicaid recipients with HIV. AIDS (IF 3.8) Pub Date : 2024-02-22 Ira B Wilson, Megan B Cole, Yoojin Lee, Theresa I Shireman, Amy C Justice, Momotazur Rahman
To determine how aging impacts health care utilization in persons with HIV (PWH) compared to persons without HIV (PWoH).
-
Explaining racial and ethnic disparities in antiretroviral therapy adherence and viral suppression among U.S. men who have sex with men. AIDS (IF 3.8) Pub Date : 2024-02-08 Deesha Patel, Linda Beer, Xin Yuan, Yunfeng Tie, Amy R Baugher, William L Jeffries, Andre Dailey, Kirk D Henny
To identify factors - including social determinants of health (SDOH) - that explain racial/ethnic disparities in antiretroviral therapy (ART) adherence and sustained viral suppression (SVS) among U.S. men who have sex with men (MSM) with HIV.
-
Age-associated dementia among older people aging with HIV in the US: a modeling study. AIDS (IF 3.8) Pub Date : 2024-02-08 Emily P Hyle, Nattanicha Wattananimitgul, Shibani S Mukerji, Julia H A Foote, Krishna P Reddy, Acadia Thielking, Liyang Yu, Anand Viswanathan, Leah H Rubin, Fatma M Shebl, Keri N Althoff, Kenneth A Freedberg
Almost 400 000 people with HIV (PWH) in the United States are over age 55 years and at risk for age-associated dementias (AAD), including Alzheimer's disease and vascular contributions to cognitive impairment and dementia (VCID). We projected the cumulative incidence and mortality associated with AAD among PWH at least 60 years in the United States compared with the general population.
-
Higher CCR5 density on CD4+ T cells in mothers and infants is associated with increased risk of in-utero HIV-1 transmission. AIDS (IF 3.8) Pub Date : 2024-02-08 Sharon Shalekoff, Bianca Da Costa Dias, Shayne Loubser, Renate Strehlau, Louise Kuhn, Caroline T Tiemessen
CCR5-tropic viruses are preferentially transmitted during perinatal HIV-1 infection. CCR5 density on CD4+ T cells likely impacts susceptibility to HIV-1 infection.
-
Relationships between plasma neurofilament light chain protein, cognition, and brain aging in people with HIV. AIDS (IF 3.8) Pub Date : 2024-02-07 Sarah A Cooley, Kalen J Petersen, Caitlin Tice, Dianne Langford, Tricia H Burdo, June Roman, Beau M Ances
Neurofilament light chain protein (NfL) is a marker of neuronal injury and neurodegeneration. Typically assessed in cerebrospinal fluid, recent advances have allowed this biomarker to be more easily measured in plasma. This study assesses plasma NfL in people with HIV (PWH) compared to people without HIV (PWoH), and its relationship with cognitive impairment, cardiovascular risk, and a neuroimaging
-
Examining Incidence of Diabetes in People Living with HIV: Tracking the Shift in Traditional and HIV-related Risk Factors. AIDS (IF 3.8) Pub Date : 2024-02-06 Gazi Sakir Mohammad Pritom, Xueying Yang, Haoyuan Gao, Shujie Chen, Jiajia Zhang, Bankole Olatosi, Xiaoming Li
The risk factors of diabetes mellitus (DM) in people with HIV (PWH) may be dynamic in a life course manner. This study aimed to describe incidence of DM and investigate the trajectory of changes in risk factor associated with DM incidence over around 15 years among a statewide cohort of PWH in South Carolina (SC).
-
Monitoring immune recovery on HIV therapy: critical, helpful, or waste of money in the current era? AIDS (IF 3.8) Pub Date : 2024-02-02 Margaretta Gergen, Austin Hewitt, Cristina B Sanger, Rob Striker
An infographic is available for this article at:http://links.lww.com/QAD/D115.
-
Specific plasma microRNAs are associated with CD4+ T-cell recovery during suppressive antiretroviral therapy for HIV-1. AIDS (IF 3.8) Pub Date : 2024-02-02 Stefanie Kroeze, Neeltje A Kootstra, Ad C van Nuenen, Theresa M Rossouw, Cissy M Kityo, Margaret Siwale, Sulaimon Akanmu, Kishor Mandaliya, Marleen de Jager, Pascale Ondoa, Ferdinand W Wit, Peter Reiss, Tobias F Rinke de Wit, Raph L Hamers
This study investigated the association of plasma microRNAs before and during antiretroviral therapy (ART) with poor CD4+ T-cell recovery during the first year of ART.
-
Sexual behaviours and risk with women in MSM in sub-Saharan Africa. AIDS (IF 3.8) Pub Date : 2024-02-01 Marion Fiorentino, Nathan Yanwou, Robinson Gravier-Dumonceau Mazelier, August Eubanks, Perrine Roux, Christian Laurent, Bruno Spire
In sub-Saharan Africa (SSA), MSM - a high HIV prevalence group - experience strong social stigma and pressure to have female partners. Accordingly, they could constitute a bridging group for HIV transmission to cisgender women. We developed a multilevel summary of MSM sexual behaviors and risk with women in various SSA regions. Following PRISMA guidelines, we conducted a mixed-method systematic review
-
Criteria for classification, nomenclature, and reference sequence selection for HIV sub-subtypes of CRF01_AE and CRF07_BC strains in China. AIDS (IF 3.8) Pub Date : 2024-02-01 Dong Wang, Yi Feng, Yuhua Ruan, Lingjie Liao, Jingjing Hao, Chang Song, Jing Hu, Yiming Shao, Hui Xing
The available knowledge regarding classification, nomenclature, and reference sequence selection for the various sub-subtypes of circulating recombinant forms (CRFs) is inadequate to fulfill the growing demands of research focused on HIV prevention. We analyzed the spread of CRF01_AE and CRF07_BC strains, mainly in China, to complement and update the existing nomenclature and to propose a reference
-
People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they? AIDS (IF 3.8) Pub Date : 2024-02-01 Claudia Bartalucci, Federico Baldi, Elena Ricci, Giancarlo Orofino, Barbara Menzaghi, Sergio Ferrara, Giovanni Francesco Pellicano', Nicola Squillace, Eleonora Sarchi, Emanuele Pontali, Giovanni Cenderello, Olivia Bargiacchi, Matteo Piccica, Maria Aurora Carleo, Antonio Cascio, Giuseppe Vittorio De Socio, Paolo Bonfanti, Antonio Di Biagio
Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria
-
Comparison of dolutegravir- and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV; a DolPHIN2 substudy. AIDS (IF 3.8) Pub Date : 2024-01-26 Lena van der Wekken-Pas, Sylvia Nassiwa, Thokozule Malaba, Mohammed Lamorde, Landon Myer, Catriona Waitt, Helen Reynolds, Saye Khoo, Nengjie He, Liesbeth van Leeuwen, David Burger, Duolao Wang, Angela Colbers
Both dolutegravir and efavirenz are known to be effective in pregnancy and post-partum to prevent vertical transmission of HIV and to maintain maternal health. Both drugs have also been associated with neuropsychiatric symptoms. To what extent these symptoms occur in pregnant and post-partum women, however, is not yet known.
-
Associations between social determinants of health and co- and multi-morbidity in people of Black ethnicities with HIV. AIDS (IF 3.8) Pub Date : 2024-01-24 Lourdes Dominguez-Dominguez, Lucy Campbell, Birgit Barbini, Julie Fox, Elena Nikiphorou, Louise Goff, Heidi Lempp, Shema Tariq, Lisa Hamzah, Frank A Post
Social Determinants of Health (SDH) are important determinants of long-term conditions and multimorbidity in the general population. The intersecting relationship between SDH and multimorbidity in people with HIV remains poorly studied.
-
Racial inequities in HIV incidence among men who have sex with men prior to and amidst an Ending the HIV Epidemic initiative. AIDS (IF 3.8) Pub Date : 2024-01-23 Kelly E Jamison, Sarah L Braunstein, Preeti Pathela
The aim of this study was to examine trends in HIV incidence among MSM relative to the scale up of Ending the HIV Epidemic (EHE) initiatives, including biomedical prevention strategies, and to describe racial inequities over time.
-
Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations: a focus on novel dual regimens. AIDS (IF 3.8) Pub Date : 2024-01-16 Dario Cattaneo, Simone Pagano, Martina Laura Colombo, Andrea Giacomelli, Andrea Gori, Cristina Gervasoni
Dolutegravir is widely used in different dual and triple antiretroviral regimens. Here, we sought to investigate the effect of the companion antiretroviral drug(s) on dolutegravir plasma trough concentrations in persons with HIV, with a focus on dual regimens.
-
Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe. AIDS (IF 3.8) Pub Date : 2024-01-16 Vinie Kouamou, Tendai Washaya, Tichaona Mapangisana, Chiratidzo Ellen Ndhlovu, Justen Manasa
Dolutegravir (DTG)-based ART is being scaled up in Africa. However, clinical experience with DTG and patterns of HIV drug resistance (HIVDR) are sparse in Zimbabwe. We assessed virological, weight, and HIVDR outcomes among individuals initiating on a DTG-based ART.
-
Comparison of HIV prevalence, incidence, and viral load suppression in Zambia population-based HIV impact assessments from 2016 and 2021. AIDS (IF 3.8) Pub Date : 2024-01-15 Lloyd B Mulenga, Jonas Z Hines, Kristen A Stafford, Kumbutso Dzekedzeke, Suilanji Sivile, Brianna Lindsay, Mumbi Chola, Faith Ussery, Hetal K Patel, Alash'le Abimiku, Sehin Birhanu, Peter Minchella, Thomas Stevens, Brave Hanunka, Tina Chisenga, Aaron Shibemba, Sombo Fwoloshi, Mwiche Siame, John Mutukwa, Lameck Chirwa, Mpanji Siwingwa, Gina Mulundu, Chinedu Agbakwuru, Prichard Mapondera, Mervi Detorio
The Zambian government has implemented a public health response to control the HIV epidemic in the country. Zambia conducted a population-based HIV impact assessment (ZAMPHIA) survey in 2021 to assess the status of the HIV epidemic to guide its public health programs.
-
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size. AIDS (IF 3.8) Pub Date : 2024-01-15 Maggie C Duncan, F Harrison Omondi, Natalie N Kinloch, Hope R Lapointe, Sarah Speckmaier, Nadia Moran-Garcia, Tanya Lawson, Mari L DeMarco, Janet Simons, Daniel T Holmes, Christopher F Lowe, Nic Bacani, Paul Sereda, Rolando Barrios, Marianne Harris, Marc G Romney, Julio S G Montaner, Chanson J Brumme, Mark A Brockman, Zabrina L Brumme
The immunogenic nature of COVID-19 mRNA vaccines led to some initial concern that these could stimulate the HIV reservoir. We analyzed changes in plasma HIV loads (pVL) and reservoir size following COVID-19 mRNA vaccination in 62 people with HIV (PWH) receiving antiretroviral therapy (ART), and analyzed province-wide trends in pVL before and after the mass vaccination campaign.
-
Mediation analysis of CKD risk factors using kidney biomarkers in women living with HIV. AIDS (IF 3.8) Pub Date : 2024-01-15 Kristienne A Edrosolan, Michael G Shlipak, Rebecca Scherzer, Michelle M Estrella, Deborah Gustafson, Roksana Karim, Molly Fisher, Mardge Cohen, Seble Kassaye, Julie Dumond, Alison Abraham, Charles E Mcculloch, Simon B Ascher
Novel urinary biomarkers reflecting kidney tubule health are associated with chronic kidney disease (CKD) risk in persons living with HIV. However, it is unknown whether these biomarkers provide mechanistic insight into the associations between clinical risk factors for CKD and subsequent CKD risk.
-
HIV viral suppression in children and adolescents two years after transition to dolutegravir: a multicentre cohort study. AIDS (IF 3.8) Pub Date : 2024-01-10 Akash Devendra, Maurus Kohler, Motlatsi Letsika, Hape Khooa, Lipontso Motaboli, Malebanye Lerotholi, Nadine Tschumi, Niklaus D Labhardt, Jennifer A Brown
Treatment failure is common among children and adolescents with HIV. Antiretroviral therapy (ART) containing dolutegravir has recently been rolled out across Africa, though long-term real-world data in paediatric populations are lacking. Here, we report treatment outcomes among children and adolescents in Lesotho who transitioned from non-nucleoside reverse transcriptase inhibitor- (NNRTI-) to dolutegravir-based
-
How the COVID-19 pandemic and the health system's response reduced HIV testing and increased late diagnoses in Mexico. AIDS (IF 3.8) Pub Date : 2024-01-09 Fernando Macías-González, Heleen Vermandere, Alicia Piñeirúa-Menendez, Sergio Bautista-Arredondo
This study aims to evaluate the disruption in HIV screening and diagnoses due to the COVID-19 pandemic and to investigate the pandemic's subsequent influence on the HIV epidemic.
-
COVID-related excess missed HIV diagnoses in the United States in 2021: follow-up to 2020. AIDS (IF 3.8) Pub Date : 2024-01-05 Alex Viguerie, Ruiguang Song, Anna Satcher Johnson, Cynthia M Lyles, Angela Hernandez, Paul G Farnham
:COVID-19 and related disruptions led to a significant decline in HIV diagnoses in the US in 2020. A previous analysis estimated 18% fewer diagnoses than expected among persons with HIV (PWH) acquiring infection in 2019 or earlier, suggesting that the decline in overall diagnoses cannot be attributed solely to decreased transmission. This analysis evaluates the progress made towards closing the 2020
-
Evaluation of the prevention of mother-to-child transmission of HIV programs at the second immunization visit in Burkina Faso and Zambia. AIDS (IF 3.8) Pub Date : 2024-01-04 Souleymane Tassembedo, Mwiya Mwiya, Anais Mennecier, Chipepo Kankasa, Paulin Fao, Jean Pierre Molès, Dramane Kania, Catherine Chunda-Liyoka, Leticia Delphine Sakana, Morgana D'Ottavi, Ajani Ousmane Taofiki, David Rutagwera, M M Wilfried-Tonga, Thorkild Tylleskär, Nicolas Nagot, Philippe Van De Perre
Our study aimed to assess the PMTCT indicators in Burkina Faso and Zambia using a patient-orientated innovative strategy based on the second visit in the Expanded Program on Immunization (EPI-2) visit at 6-8 weeks.
-
The association of Changes In Depression Severity After The Onset of The Covid-19 Pandemic and Viral Non-Suppression Among People With HIV. AIDS (IF 3.8) Pub Date : 2023-12-29 Tarfa Verinumbe, Catherine R Lesko, Richard D Moore, Anthony T Fojo, Jeanne Keruly, LaQuita N Snow, Heidi Hutton, Geetanjali Chander, Jarratt D Pytell, Oluwaseun Falade-Nwulia
This study sought to characterize changes in depressive symptom severity during the COVID-19 pandemic and the association of these changes with HIV viral nonsuppression among people with HIV (PWH).
-
PrEP Availability Among Health Facilities Participating in the Global IeDEA Consortium. AIDS (IF 3.8) Pub Date : 2023-12-22 Samuel Kebede, Ellen Brazier, Aimee M Freeman, Timothy R Muwonge, Jun Yong Choi, Renee de Waal, Armel Poda, Carina Cesar, Athanase Munyaneza, Charles Kasozi, Mark Kristoffer U Pasayan, Keri N Althoff, Alisho Shongo, Nicola Low, Didier Ekouevi, Valdiléa G Veloso, Jonathan Ross
While recognized as a key HIV prevention strategy, preexposure prophylaxis (PrEP) availability and accessibility are not well documented globally. We aimed to describe PrEP drug registration status and the availability of PrEP services across HIV care sites participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) research consortium.
-
Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery. AIDS (IF 3.8) Pub Date : 2023-12-21 John Patrick Thornhill, Julie Fox, Genevieve Elizabeth Martin, Rebecca Hall, Julianne Lwanga, Heather Lewis, Helen Brown, Nicola Robinson, Kristen Kuldanek, Sabine Kinloch, Nneka Nwokolo, Gary Whitlock, Sarah Fidler, John Frater
:We present findings from a large cohort of individuals treated during Primary HIV Infection (PHI) and examine the impact of time from HIV-1 acquisition to antiretroviral therapy (ART) initiation on clinical outcomes. We also examine the temporal changes in the demographics of individuals presenting with PHI to inform HIV-1 prevention strategies.
-
Life course history of physical and sexual abuse is associated with cardiovascular disease risk among women living with and without HIV. AIDS (IF 3.8) Pub Date : 2023-12-21 Allison A Appleton, Mark H Kuniholm, Elizabeth Vásquez, Mardge H Cohen, Jessica Donohue, Michelle Floris-Moore, M Reuel Friedman, David B Hanna, Matthew J Mimiaga, Caitlin A Moran, Michael W Plankey, Linda A Teplin, Sanyog G Shitole, Deanna Ware, Deborah L Jones, Jenni Wise
Sexual and physical abuse predict cardiovascular disease (CVD) among women in the general population. Women living with HIV (WLWH) report more abuse and have higher CVD risk compared to other women, yet associations between abuse history and CVD have not been considered among WLWH. This study fills this gap, and describes possible pathways linking abuse to CVD risk among WLWH and women living without
-
Optimizing behavioral and pharmacological smoking cessation interventions among people with HIV: results of a factorial design randomized trial. AIDS (IF 3.8) Pub Date : 2023-12-21 Seth Himelhoch, Deana Kelly, Chris deFilippi, Gregory Taylor, Melanie Bennett, Deborah Medoff, Lan Li, Robert Christiansen, Wendy Potts, Jonathan Shuter
People living with HIV/AIDS (PWH) smoke at nearly three times the rate of the general population. Interventions to promote sustained quitting among PWH are urgently needed.
-
Maternal immunization in women living with HIV. AIDS (IF 3.8) Pub Date : 2023-12-20 Nicolas Dauby, Amandine Gagneux-Brunon, Charlotte Martin, Marisa Márcia Mussi-Pinhata, Tessa Goetghebuer
Thanks to widespread use of antiretroviral therapy worldwide, women living with HIV (WLWH) are becoming pregnant and giving birth to HIV-exposed but uninfected (HEU) newborns. Both pregnancy and HIV infection-related factors such as low CD4+ T-cell count or uncontrolled viral load increase the risk of severe infections such as influenza, COVID-19, and others, making maternal immunization a valuable
-
The impact of obesity on doravirine exposure in people with HIV. AIDS (IF 3.8) Pub Date : 2023-12-20 Leena Zino, Lianne P M van Bussel, Rick Greupink, Manon Marneef, David M Burger, Angela Colbers
Obesity incidence is increasing among people with HIV. Doravirine is a recommended first-line antiretroviral drug in many countries with no data from people with obesity. This study investigates the exposure of doravirine 100 mg standard dose in obese versus normal weight patients using clinical data combined with physiologically based pharmacokinetic modelling. Results from both approaches showed
-
Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy. AIDS (IF 3.8) Pub Date : 2023-12-19 Jienchi Dorward, Katya Govender, Pravikrishnen Moodley, Richard Lessells, Natasha Samsunder, Yukteshwar Sookrajh, Thomas R Fanshawe, Philip J Turner, Christopher C Butler, Paul K Drain, Gail N Hayward, Nigel Garrett
We aimed to determine whether urine tenofovir (TFV) and dried blood spot (DBS) tenofovir diphosphate (TFV-DP) concentrations are associated with concurrent HIV viraemia.
-
Assessing transmission attribution risk from simulated sequencing data in HIV molecular epidemiology. AIDS (IF 3.8) Pub Date : 2023-12-19 Fabrícia F Nascimento, Sanjay R Mehta, Susan J Little, Erik M Volz
HIV molecular epidemiology (ME) is the analysis of sequence data together with individual-level clinical, demographic, and behavioral data to understand HIV epidemiology. The use of ME has raised concerns regarding identification of the putative source in direct transmission events. This could result in harm ranging from stigma to criminal prosecution in some jurisdictions. Here we assessed the risks
-
Quantifying the association of individual-level characteristics with disparities in kidney transplant waitlist addition among people with HIV. AIDS (IF 3.8) Pub Date : 2023-12-14 Brittany A Shelton, Bisakha Sen, David J Becker, Paul A MacLennan, Henna Budhwani, Jayme E Locke
Over 45% of people with HIV (PWH) in the United States ≥50 years old and are at heightened risk of aging-related comorbidities including end-stage kidney disease (ESKD), for which kidney transplant is the optimal treatment. Among ESKD patients, PWH have lower likelihood of waitlisting, a requisite step in the transplant process, than individuals without HIV. It is unknown what proportion of the inequity
-
The relationship between alcohol consumption and risk of HIV in married men: a multi-country study on Sub-Saharan Africa. AIDS (IF 3.8) Pub Date : 2023-12-13 Lukas König, Petal Petersen Williams, Paul A Shuper, Charlotte Probst
A key factor for incidence of HIV is alcohol consumption. It impacts judgment and the probability to overlook risk-relevant information, which creates a pathway to reduced adherence to biomedical prevention and engagement in condomless sex. We strengthen the understanding of the link between alcohol consumption and risk of HIV among married men in Sub-Saharan Africa (SSA), as we use comprehensive population-level
-
Cerebrospinal fluid CXCL13 concentration for diagnosis and monitoring of neurosyphilis in people living with hiv. a prostective cohort study. AIDS (IF 3.8) Pub Date : 2023-12-12 Ricardo de S Carvalho, Isabelle de C Rangel, Michel M Soane, Natália B B Saraiva, Victor Herbst, Fernando R A Ferry
The study aimed to assess and compare CSF-CXCL13 levels in People Living with HIV (PLWH) with suspected neurosyphilis (NS), those with syphilis but without NS, and patients without treponema infection. Additionally, it aimed to evaluate changes in CSF-CXCL13 concentrations before and after antibiotic treatment.
-
Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes. AIDS (IF 3.8) Pub Date : 2023-12-11 Amanda Mocroft, Annegret Pelchen-Matthews, Jennifer Hoy, Josep M Llibre, Bastian Neesgaard, Nadine Jaschinski, Pere Domingo, Line Dahlerup Rasmussen, Huldrych F Günthard, Bernard Surial, Angela Öllinger, Michael Knappik, Stephan De Wit, Ferdinand Wit, Cristina Mussini, Joerg Vehreschild, Antonella D'Arminio Monforte, Anders Sonnerborg, Antonella Castagna, Alain Volny Anne, Vani Vannappagari, Cal Cohen
People with HIV and extensive antiretroviral exposure may have limited/exhausted treatment options (LExTO) due to resistance, comorbidities, or antiretroviral-related toxicity. Predictors of LExTO were investigated in the RESPOND cohort.
-
Measles seroprevalence in adolescents and young adults living with HIV and response to MMR booster in seronegative ones. AIDS (IF 3.8) Pub Date : 2023-12-07 Raquel M Simakawa, Beatriz C Araújo, Erika Ono, M Isabel De Moraes-Pinto, Regina C M Succi
The study analyzed people with HIV (PWH) measles seroprevalence and response to MMR booster given to seronegative individuals.
-
Use of a machine learning model to predict retention in care in an urban HIV clinic. AIDS (IF 3.8) Pub Date : 2023-12-07 Sarah A Schmalzle, Demetri Maroosis, Henry Masur, Shyam Kottilil, Poonam Mathur
Identifying barriers to retention in care (RIC) is critical to ending the HIV epidemic in the United States. Therefore, we developed a machine learning model (MLM) to identify predictive factors for RIC in an urban HIV clinic. Our MLM yielded a positive predictive value of 84%, higher than previously reported MLMs. We found that MLM can be used to develop interventional strategies to enhance RIC in
-
Dysbiosis of gut microbiota and metabolites during AIDS: implications for CD4+ T cell reduction and immune activation. AIDS (IF 3.8) Pub Date : 2023-12-07 Jie Zhou, Yuecong Yang, Zhiman Xie, Dongjia Lu, Jinping Huang, Liuyang Lan, Baodong Guo, Xiping Yang, Qing Wang, Zhuoxin Li, Yu Zhang, Xing Yang, Sufang Ai, Ningmei Liu, Hao Liang, Li Ye, Jiegang Huang
Identifying the gut microbiota associated with host immunity in the AIDS stage.
-
Bone turnover change after randomised switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV. AIDS (IF 3.8) Pub Date : 2023-12-07 Amelia E B Moore, James E Burns, Deirdre Sally, Ana Milinkovic, Georgios Krokos, Joemon John, Christopher Rookyard, Alessandro Borca, Erica R M Pool, Anna Tostevin, Alyss Harman, Dwight S Dulnoan, Musib Siddique, Richard Gilson, Alejandro Arenas-Pinto, Gary J R Cook, John Saunders, David Dunn, Glen M Blake, Sarah L Pett
Bone loss in people with HIV (PWH) is poorly understood. Switching tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has yielded bone mineral density (BMD) increases. PETRAM (NCT#:03405012) investigated whether BMD and bone turnover changes correlate.
-
The clinical utility of three frailty measures in identifying HIV-associated neurocognitive disorders. AIDS (IF 3.8) Pub Date : 2023-12-04 David J Moore, Ni Sun-Suslow, Ariadne A Nichol, Emily W Paolillo, Rowan Saloner, Scott L Letendre, Jennifer Iudicello, Erin E Morgan
Frailty measures vary widely and the optimal measure for predicting HIV-associated neurocognitive disorders (HAND) is unclear.
-
The immunogenicity of an HIV-1 gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy. AIDS (IF 3.8) Pub Date : 2023-12-04 Jeffrey M Jacobson, Barbara K Felber, Huichao Chen, George N Pavlakis, James I Mullins, Stephen C de Rosa, Daniel R Kuritzkes, Georgia D Tomaras, Jennifer Kinslow, Yajing Bao, Maxine Olefsky, Margherita Rosati, Jenifer Bear, Drew Hannaman, Gregory M Laird, Joshua C Cyktor, Sonya L Heath, Ann C Collier, Susan L Koletar, Babafemi O Taiwo, Pablo Tebas, David A Wohl, Pablo F Belanzauran-Zamudio, M Juliana
The primary objective of the study was to assess the immunogenicity of an HIV-1 Gag conserved element DNA vaccine (p24CE DNA) in people with HIV (PWH) receiving suppressive antiretroviral therapy (ART).
-
The Association between anticholinergic/sedative burden and physical frailty in people aging with HIV. AIDS (IF 3.8) Pub Date : 2023-12-04 Henry Ukachukwu Michael, Marie-Josée Brouillette, Robyn Tamblyn, Lesley K Fellows, Nancy E Mayo
This study aimed to estimate the strength of the association between anticholinergic/sedative burden and concurrent physical frailty in people aging with HIV.
-
Ending the HIV Epidemic in the US: lessons from Eswatini. AIDS (IF 3.8) Pub Date : 2023-11-28 Jessica Justman,Connor Wright,Wafaa M El-Sadr
-
Effect of TB-HIV co-treatment on clinical and growth outcomes among hospitalized children newly initiating antiretroviral therapy. AIDS (IF 3.8) Pub Date : 2023-11-28 Ashenafi S Cherkos, Lisa M Cranmer, Irene Njuguna, Sylvia M LaCourse, Cyrus Mugo, Hellen Moraa, Elizabeth Maleche-Obimbo, Daniel A Enquobahrie, Barbra A Richardson, Dalton Wamalwa, Grace John-Stewart
Evaluate effects of TB-HIV co-treatment on clinical and growth outcomes in children with HIV (CHIV).
-
Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation. AIDS (IF 3.8) Pub Date : 2023-11-28 Camilla Tincati, Valeria Bono, Elvira Stefania Cannizzo, Delfina Tosi, Federica Savi, Camilla Falcinella, Anna Casabianca, Chiara Orlandi, Carmelo Luigiano, Matteo Augello, Stefano Rusconi, Antonio Muscatello, Alessandra Bandera, Andrea Calcagno, Andrea Gori, Silvia Nozza, Giulia Marchetti
Impairment of the gastrointestinal (GI) barrier leads to microbial translocation and peripheral immune activation which are linked to disease progression. Data in the setting of primary HIV/SIV infection suggest that gut barrier damage is one of the first events of the pathogenic cascade, preceding mucosal immune dysfunction and microbial translocation. We assessed gut structure and immunity as well
-
Ambient particulate matter and renal function decline in HIV/AIDS patients: exploring the mediating role of TyG index. AIDS (IF 3.8) Pub Date : 2023-11-28 Hongfei Ma, Wei Liang, Aojing Han, Qian Zhang, Shun Gong, Yang Bai, Daiming Gao, Hao Xiang, Xia Wang
We aimed to explore the effect of particulate matter (PM) exposure on renal function in people living with HIV/AIDS (PWHA).
-
The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants: a modelling study. AIDS (IF 3.8) Pub Date : 2023-11-28 Leigh F Johnson, Landon Myer, Lise Jamieson, Gesine Meyer-Rath, Sinead Delany-Moretlwe, Dvora Joseph Davey
Pregnant and breastfeeding women (PBW) in sub-Saharan Africa have high HIV incidence rates and associated risk of vertical transmission to their infants. Oral pre-exposure prophylaxis (PrEP) and injectable PrEP (long-acting cabotegravir, or CAB-LA) can potentially reduce this HIV transmission, but population-level impacts are uncertain.
-
Association of age at ART initiation with CD4:CD8 ratio recovery among virally suppressed people living with HIV, 2001-2019. AIDS (IF 3.8) Pub Date : 2023-11-28 Clare J Holden, Fiona C Lampe, Fiona M Burns, Clinton Chaloner, Margaret Johnson, Sabine Kinloch-De Loes, Colette J Smith
To investigate the association of age at anti-retroviral therapy (ART) initiation with CD4:CD8 T cell ratio in virally suppressed people with HIV on long-term ART, and to characterize potential CD4:CD8 ratio recovery in this population by age.
-
Fetal growth assessed via ultrasound in relation to maternal HIV infection status and antiretroviral regimens. AIDS (IF 3.8) Pub Date : 2023-11-22 Paige L Williams, Brad Karalius, Kunjal Patel, Ann Aschengrau, Nahida Chakhtoura, Naomi Enriquez, Jack Moye, Patricia A Garvie, Dina Monte, George R Seage, Carmen Zorrilla, Marisa M Mussi-Pinhata
:To evaluate effects of maternal HIV and antiretroviral treatment (ART) on intrauterine fetal growth.
-
Perinatal HIV infection is associated with deficits in muscle function in children and adolescents: a cross-sectional study in Zimbabwe. AIDS (IF 3.8) Pub Date : 2023-11-22 Celia L Gregson, Andrea M Rehman, Ruramayi Rukuni, Cynthia Mukwasi-Kahari, Tafadzwa Madanhire, Farirayi Kowo-Nyakoko, Mícheál Ó Breasail, Lisha Jeena, Grace Mchugh, Suzanne Filteau, Joseph Chipanga, Victoria Simms, Hilda Mujuru, Kate A Ward, Rashida A Ferrand
:To determine how muscle strength, power, mass, and density (i.e. quality) differ between children living with HIV (CWH) and those uninfected, and whether antiretroviral therapy (ART) regime is associated with muscle quality.
-
Weight loss associated with semaglutide treatment among people with HIV. AIDS (IF 3.8) Pub Date : 2023-11-17 Lara Haidar, Heidi M Crane, Robin M Nance, Allison Webel, Stephanie A Ruderman, Bridget M Whitney, Amanda L Willig, Sonia Napravnik, L Sarah Mixson, Christine Leong, Alekhya Lavu, Laila Aboulatta, Mindy Dai, Andrew Hahn, Michael S Saag, Laura Bamford, Edward Cachay, Mari M Kitahata, Kenneth H Mayer, Jeffrey Jacobson, Richard D Moore, Joseph A C Delaney, Lydia N Drumright, Sherif Eltonsy
There is limited real-world evidence about the effectiveness of semaglutide for weight loss among people with HIV (PWH). We aimed to investigate weight change in a US cohort of PWH who initiated semaglutide treatment.
-
HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection. AIDS (IF 3.8) Pub Date : 2023-11-16 Laurie A VanderVeen, Lisa Selzer, Brian Moldt, Aiyappa Parvangada, Jiani Li, Jintanat Ananworanich, Trevor A Crowell, Joseph J Eron, Eric S Daar, Richard Haubrich, Romas Geleziunas, Joshua Cyktor, John W Mellors, Christian Callebaut
We studied the relationship between viral diversity and susceptibility to broadly neutralizing antibodies (bNAbs) in longitudinal plasma and peripheral blood mononuclear cells from 89 people with HIV who initiated antiretroviral therapy (ART) during acute and early HIV-1 infection (AEHI). HIV-1 diversity and predicted bNAb susceptibility were comparable across AEHI. Diversity evolution was not observed
-
Predicting acute kidney injury: do we need biomarkers? AIDS (IF 3.8) Pub Date : 2023-11-16 David R Chadwick,Frank A Post